Levi Strauss에 대한 매도 수량은 투자자에게 Levi Strauss의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Levi Strauss (NYSE:LEVI) 주식, 공매도 수량 보고

Levi Strauss

Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver; Europe; and Asia.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

ANGO

BIGC

LEVI

PCSA

목요일 아침 (현지 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 1. 월스트리트는 컨스텔레이션 브랜드(NYSE:STZ)가 분기 이익을 주당 4.08달러, 매출 29억 달러로 발표할 것으로 예상하고 있다. 컨스텔레이션 주식은 애프터 마켓에서 0.3% 하락한 254.90달러로 거래되고 있다.

목요일 주목해야 할 주식: 컨스텔레이션 브랜드, 리바이 스트라우스 그리고 3종목

Equities

리바이 스트라우스 앤 컴퍼니(NYSE:LEVI)는 수요일 다커스(Dockers) 브랜드 판매를 고려하고 있음을 밝혔다. 이 발표 이후 회사 주가는 시간외 거래에서 10% 이상 하락했다.

리바이 스트라우스, 다커스 브랜드 매각 고려 중: 상징적인 데님 브랜드에 미치는 영향

After-Hours Center

Movers

리바이 스트라우스 앤 컴퍼니(NYSE:LEVI)의 주가는 수요일 마감 후 발표된 회사의 3분기 재무 결과에 따라 시간외 거래에서 9% 이상 하락했다. 보고서의 세부 내용은 다음과 같다.

리바이 스트라우스의 주식은 엇갈린 3분기 실적 발표 후 시간외 거래에서 9% 이상 급락

Levi Strauss & Co

LEVIATHAN GOLD LTD by Leviathan Gold Ltd.

Leviathan Gold Ltd

Leviathan Gold Ltd Ordinary Shares

Levitee Labs Inc

SoundHound AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) shares are trading higher by 4.1% to $17.63 Monday morning. The stock rose some 23.7% on Friday following several notable announcements from the company regarding <a href="https://www.benzinga.com/pressreleases/24/12/b42461221/soundhound-ais-amelia-platform-recognized-as-frost-radar-leader-in-enterprise-conversational-ai-in">conversational AI</a>.
What Happened: The company&#8217;s Amelia Conversational AI Platform was named a leader in Frost &amp; Sullivan&#8217;s 2024 Frost Radar for Enterprise Conversational AI in Healthcare. 
The report highlighted SoundHound's innovative use of natural language processing and large language models to enhance healthcare operations, such as patient engagement and administrative workflows.
Analysts praised the company's innovation pipeline and strategic focus, noting its recent acquisition of Amelia as a key driver for expanded opportunities in healthcare. The enterprise conversational AI market in healthcare is projected to reach $2.34 billion by 2027, growing at 17.2% annually.
In addition, SoundHound partnered with Church's Texas Chicken to deploy voice AI technology for drive-thru orders, streamlining operations and reducing wait times.
"Integrating our technology into Church's Texas Chicken restaurants marks a significant milestone in drive-thru innovation," said James Hom, Chief Product Officer at SoundHound AI.
Read Also: <a href="https://www.benzinga.com/24/12/42504194/us-stocks-to-open-higher-ahead-of-feds-decision-this-week-analyst-says-santa-comes-later-in-december">U.S. Stocks To Open Higher Ahead Of Fed&#8217;s Decision This Week: Analyst Says &#8216;Santa Comes Later In December&#8217;</a>
<h2 class="wp-block-heading">How To Buy SOUN Stock</h2>
By now you're likely curious about how to participate in the market for SoundHound AI &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
In the the case of SoundHound AI, which is trading at $16.91 as of publishing time, $100 would buy you 5.91 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SOUN has a 52-week high of $17.29 and a 52-week low of $1.62.

SOUN

What's Going On With SoundHound AI Stock?

JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLBT#NASDAQ">CLBT</a>) with a Overweight and raises the price target from $22 to $24.

Price Target

Analyst Ratings

CLBT

JP Morgan Maintains Overweight on Cellebrite DI, Raises Price Target to $24

As the tech sector pivots from <a href="https://www.benzinga.com/topic/artificial-intelligence">AI-fueled growth</a> to a broader market recovery, JPMorgan analyst Samik Chatterjee highlights a cyclical rebound powering upside for traditional IT infrastructure and industrial tech.
Top picks like Dell Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>), Corning Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) and Coherent Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) are set to ride the next cyclical upswing from recovering demand in servers, telecom, and industrial markets. 
At the same time, the analyst says Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>), Cisco Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) and Amphenol Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) stand to gain from networking and multi-sector recoveries.
<h2 class="wp-block-heading">Why These Three?</h2>
Chatterjee's strategy banks on recovery beyond AI-driven hype. 
<ul>
<li>The resurgence of traditional IT infrastructure demand should position Dell for long-term growth. Infrastructure investments and enterprise upgrades are expected to spearhead Dell's upside.</li>
</ul>
<ul>
<li>Corning brings its diversified industrial tech portfolio to the table. With AI-driven telecom growth and a revival in optical and display markets, Corning is poised to shine as end-market recoveries take center stage.</li>
</ul>
<ul>
<li>Coherent, a player in the optical sector, rounds out the trio with its diversified revenue streams. Chatterjee points to margin-expansion opportunities and AI-related synergies as key drivers for this pick, particularly as the company works through inventory digestion challenges.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/news/24/11/42231610/microsoft-hp-dell-ramp-up-parts-production-in-china-ahead-of-trumps-return-to-white-house">Microsoft, HP, Dell Race To Ramp Up Production In China As Trump&#8217;s Tariff Threat Looms Ahead Of His White House Return</a>
<h2 class="wp-block-heading">A Broader Tailwind Beyond AI &#8211; Arista, Cisco, Amphenol</h2>
The report underscores a robust cyclical resurgence in critical hardware and networking sectors. After experiencing downturns in late 2023 and early 2024, traditional IT infrastructure markets—encompassing servers, storage, and enterprise networking—are showing signs of substantial recovery. The analyst says companies like Arista Networks, Cisco, and Amphenol are strategically positioned to capitalize on these emerging networking opportunities and multi-market rebounds.
The PC market, for example, is expected to shift gears in 2025, with enterprise/commercial refreshes driving mid-single-digit growth. Similarly, the smartphone market, already seeing modest growth in 2024, is forecasted to accelerate next year, boosted by subsidies in China.
On the networking front, datacenter switches and wireless LANs are primed for the most substantial rebounds in 2025, reflecting enterprises' push toward datacenter investments. 
This sets the stage for Arista and Cisco, both benefiting from secular shifts in cloud and AI-driven networking.
<h2 class="wp-block-heading">Dell, Corning, Coherent Lead The Charge</h2>
JPMorgan's call for a cyclical rebound beyond AI hype highlights a return to fundamentals, with Dell, Corning, and Coherent leading the charge. 
With broader end markets poised for recovery, these names stand out as key beneficiaries in the next phase of tech and industrial growth.
Investors looking for opportunities in a post-AI frenzy market may find this pivot toward a cyclical recovery both timely and lucrative.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42504194/us-stocks-to-open-higher-ahead-of-feds-decision-this-week-analyst-says-santa-comes-later-in-december">US Stocks To Open Higher Ahead Of Fed&#8217;s Decision This Week: Analyst Says &#8216;Santa Comes Later In December&#8217;</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

Tech

ANET

COHR

CSCO

DELL

Dell, Corning, Coherent: JPMorgan's Top Picks For Cyclical Recovery 'Beyond AI'

JP Morgan analyst Brian Essex maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Overweight and raises the price target from $372 to $418.

CRWD

JP Morgan Maintains Overweight on CrowdStrike Holdings, Raises Price Target to $418

JMP Securities analyst Jonathan Wolleben reiterates Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) from Market Perform to Market Perform.

Reiteration

ABNB

JMP Securities Reiterates Market Perform on Airbnbto Market Perform

JP Morgan analyst Brian Essex maintains CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) with a Overweight and raises the price target from $355 to $375.

CYBR

JP Morgan Maintains Overweight on CyberArk Software, Raises Price Target to $375

Monness, Crespi, Hardt analyst Brian White downgrades MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) from Neutral to Sell and announces $220 price target.

Downgrades

Monness, Crespi, Hardt Downgrades MongoDB to Sell, Announces $220 Price Target

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) has briefly crossed the $106,000 threshold during the Asian trading session before falling back below $104,000 before the New York open. 
Market observers expect Bitcoin to continue to push up but are divided on how long the <a href="https://www.benzinga.com/money/bitcoin-price-prediction">rally can last.</a>
What Happened: Crypto trader Scient <a href="https://x.com/Crypto_Scient/status/1868593716337733898">predicted</a> in a post on X on Monday predicts a local top at $110,000 near the New Year, followed by a correction to the $80,000–$84,000 range. 
He suggests the correction may bottom out around Donald Trump's inauguration on Jan. 20.
Scient believes this consolidation could set the stage for a stronger parabolic rally post-inauguration, noting that such a setup would be a healthy pivot point. However, he warns that traders may misinterpret the event as a &#8220;sell-the-news&#8221; scenario, potentially leading to over-trading and unnecessary losses.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42501517/whale-accumulation-powers-bitcoins-bull-run-but-retail-still-the-king-in-ownership">Bitcoin&#8217;s Bull Run Gets A Boost From Whale Accumulators, But Retail Still The King In Ownership</a>
In a comprehensive <a href="https://x.com/coldbloodshill/status/1868357111589044653?s=46">post</a> analyzing the state of the market, crypto trader Cold Blooded Shiller provides broader context for Bitcoin's current cycle and future outlook. He argues that the 8-month consolidation phase felt like a bear market to many but was actually a transitionary phase. The current cycle, marked by over 2 years of upward trending, has been unusually strong with shallow corrections compared to previous cycles.
The analyst notes several distinctive features of the current cycle:
<ul>
<li>The longest continuation trend with drawdowns below 50%.</li>
<li>Outperformance of Bitcoin versus altcoins with clear price action.</li>
<li>Typical bull market pullbacks, like the 30% summer correction, unlike sharper selloffs of 2021.</li>
</ul>
Shiller predicts bullish momentum in 2025, with Bitcoin and altcoins benefiting from positive catalysts, including regulatory clarity and favourable political developments. While volatility will persist, aggressive selloffs are less likely as demand grows.
Price Action: Over the past 24 hours, Bitcoin is up 1.4%, trading at $103,944 at the time of writing.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42490266/bitcoin-to-180000-ethereum-over-6000-solana-to-500-vanecks-2025-crypto-predictions">Bitcoin To $180,000, Ethereum Over $6,000, Solana To $500: VanEck&#8217;s 2025 Crypto Predictions</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Taps $106,000, Consolidates At $104,000: Why Is BTC Going Up?

The term sheet is non-binding, subject to the execution of a definitive agreement&nbsp;
Vancouver, Canada, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has signed a non-binding term sheet&nbsp; with Dr. Glitter Pty Ltd, a health technology company that has developed ActivCrystal&#x2122; technology, a world-first oral delivery format that encapsulates active ingredients in crystals that are tasteless, odorless, made from natural ingredients, and designed to be sprinkled on meals. The two companies plan to collaborate on the development and commercialization of Clearmind's proprietary MEAI-based alcohol substitute and Dr Glitter Pty Ltd's proprietary ActivCrystal&#x2122; technology. The term sheet outlines preliminary terms that, upon the mutual agreement of the parties, will be memorialized in a definitive agreement that sets forth a framework for advancing Clearmind and Dr Glitter Pty Ltd's groundbreaking innovations.
Under the terms of the term sheet, upon the execution of the definitive agreement, the parties will work together to develop MEAI-based alcohol alternative aimed to naturally replicate the known sensations from drinking alcohol without the associated health risks or hangover. In ActivCrystal&#x2122; format, Clearmind's MEAI-based alcohol alternative may be sprinkled into users' choice of beverage or food, and dosage may be varied by users individually. This collaboration has the potential to mark an important milestone in Clearmind's strategy to bring MEAI to global markets, addressing the urgent need for innovative solutions to combat alcohol misuse - a major contributor to countless annual deaths worldwide.

Biotech

General

CMND

Clearmind Medicine And Dr Glitter Pty Sign Non-Binding Term Sheet For Mutual Development Of Novel Psychedelic MEAI- Based Alcohol Substitute In ActivCrystal Format

Contracts

SAIC

CORRECTION: Science Applications International Wins Prime Position On $1.8B Personal And Readiness Infrastructure Support Management Award Task Order Contract

Maxim Group initiates coverage on Caledonia Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CMCL#AMEX">CMCL</a>) with a Buy rating and announces Price Target of $17.

Initiation

CMCL

Maxim Group Initiates Coverage On Caledonia Mining with Buy Rating, Announces Price Target of $17

MAIA

MAIA Biotechnology Announced That The FDA Has Designated THIO For The Treatment Of Pediatric-Type Diffuse High-Grade Gliomas As A Drug For A Rare Pediatric Disease

Macro Economic Events

Econ #s

Economics

NY Empire State Manufacturing Index (Dec) 0.2 vs 6.4 Est.

<a href="https://www.globenewswire.com/Tracker?data=286KhLcdBFq0jjHydlUlFgUVt3Qe1EntYrWf9_NGk2O5gQ3qmTtoUaD_m_6HgB4UopoV28RlSNF0zLXQddI0lg==">Telos Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>), an authorized enrollment provider, continues to expand locations to enroll consumers in the TSA PreCheck&#xAE; program by opening 15 new locations in Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Ohio, Tennessee, Texas and Washington. These locations began offering enrollment services today, December 16, 2024.
Telos now has 188 TSA PreCheck enrollment centers open in 29 states across the U.S. The launch of these new enrollment centers represents the ongoing expansion of Telos' national TSA PreCheck enrollment footprint. Throughout 2024 and 2025, Telos will continue delivering convenience to consumers by launching additional locations and extended hours of operation for enrollment and renewals.

Telos Corporation, An Official TSA PreCheck Enrollment Provider, Expands Enrollment And Renewal Options By Opening 15 New Locations In Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Ohio, Tennessee, Texas And Washington

TURB

Turbo Energy Provides Business Operations Update Due To Valencia, Spain Flooding; $2.3M Warehousing Was Impacted; 100% Of Losses Are Fully Covered With Reimbursement Funds Expected Within Next 60-90 Days

WIIM

Ford Motor shares are trading lower after Jefferies downgraded the stock from Hold to Underperform and cut its price target from $12 to $9.

Macquarie analyst Tao Qiu initiates coverage on Privia Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVA#NASDAQ">PRVA</a>) with a Outperform rating and announces Price Target of $25.

PRVA

Macquarie Initiates Coverage On Privia Health Gr with Outperform Rating, Announces Price Target of $25

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Stifel raised the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from $490 to $494. Stifel analyst Paul Matteis maintained a Hold rating. Vertex Pharmaceuticals shares closed at $463.73 on Friday. See how other analysts view this stock.</li>
<li>Jefferies raised the price target for Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) from $63 to $70. Jefferies analyst Akash Tewari upgraded the stock from Hold to Buy. Bristol-Myers Squibb shares closed at $55.78 on Friday. <a href="https://www.benzinga.com/quote/BMY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Oppenheimer boosted the price target for Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) from $825 to $1,065. Oppenheimer analyst Jason Helfstein maintained an Outperform rating. Netflix shares closed at $918.87 on Friday. <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley cut MKS Instruments, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) price target from $155 to $150. Morgan Stanley analyst Joseph Moore maintained an Overweight rating. MKS Instruments shares settled at $112.55 on Friday. <a href="https://www.benzinga.com/quote/MKSI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital raised RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) price target from $320 to $450. Loop Capital analyst Anthony Chukumba maintained a Hold rating. Walmart shares closed at $446.04 on Friday. <a href="https://www.benzinga.com/quote/RH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank cut NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) price target from $92 to $82. Deutsche Bank analyst Krisztina Katai maintained a Buy rating. NIKE shares closed at $77.25 on Friday.  <a href="https://www.benzinga.com/quote/NKE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt raised The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) price target from $122 to $135. Rosenblatt analyst Barton Crockett maintained a Buy rating. Disney shares closed at $113.34 on Friday. See how other analysts view this stock.</li>
<li>Mizuho cut the price target for Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) from $137 to $134. Mizuho analyst Nitin Kumar maintained a Neutral rating. Exxon Mobil shares settled at $110.84 on Friday. <a href="https://www.benzinga.com/quote/XOM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho raised CNX Resources Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNX#NYSE">CNX</a>) price target from $33 to $38. Mizuho analyst Nitin Kumar downgraded the stock from Neutral to Underperform. CNX Resources shares closed at $37.79 on Friday. <a href="https://www.benzinga.com/quote/CNX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush raised Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) price target from $400 to $515. Wedbush analyst Daniel Ives maintained an Outperform rating. Tesla shares closed at $436.23 on Friday. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying TSLA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="483" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126-1024x483.png" alt="" class="wp-image-693891" style="width:557px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126-1024x483.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126-300x142.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126-768x362.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126.png 1176w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42482639/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-with-over-6-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks With Over 6% Dividend Yields</a></li>
</ul>

MKSI

NFLX

TSLA

VRTX

Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday

- Results for all three TransCon hGH starting dose cohorts, in first clinical trial of an indication outside of growth hormone deficiency, showed a safety and tolerability profile comparable to daily somatropin
- Annualized height velocity was similar at Week 26 in once-weekly TransCon hGH-treated and daily somatropin-treated children
COPENHAGEN, Denmark, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) today announced positive Week 26 topline results from New InsiGHTS, its Phase 2 randomized, open-label, active-controlled trial in the U.S. to investigate the safety, tolerability, and efficacy of once-weekly TransCon hGH (lonapegsomatropin; approved for pediatric growth hormone deficiency) compared to daily somatropin in prepubertal children with Turner syndrome.
New InsiGHTS randomized and dosed 49 children with Turner syndrome aged 1 to 10 years old into one of four treatment groups 1:1:1:1 – one of three starting doses of TransCon hGH (0.24, 0.30, or 0.36 mg/kg/week) or an active comparator of daily somatropin with a starting dose of 0.35 mg/kg/week. Doses were individualized based on IGF-1.
<ul>
<li>On the primary endpoint of annualized height velocity and secondary endpoint of change from baseline in height SDS, children treated with TransCon hGH demonstrated improved growth similar to daily somatropin at Week 26, independent of starting dose.
<ul>
<li>In the trial, TransCon hGH was generally safe and well tolerated, with no discontinuations related to study drug and with comparable safety and tolerability to daily somatropin.</li>
</ul>
</li>
</ul>

ASND

Ascendis Pharma Presents New InsiGHTS Trial Of TransCon hGH In Turner Syndrome Achieved Primary Objective At Week 26; Results For All Three TransCon hGH Starting Dose Cohorts, In First Clinical Trial Of An Indication Outside Of Growth Hormone Deficiency, Showed A Safety And Tolerability Profile Comparable To Daily Somatropin

Macquarie analyst Tao Qiu initiates coverage on Healthcare Services Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCSG#NASDAQ">HCSG</a>) with a Neutral rating and announces Price Target of $13.

HCSG

Macquarie Initiates Coverage On Healthcare Services Group with Neutral Rating, Announces Price Target of $13

Trending stocks this week as strong jobs report underscore resilience of U.S. economy

Amid a renewed interest in denim, Levi Strauss & Co. ($LEVI) has encountered difficulties. These include disappointing revenue and declining sales ...

Levi Strauss & Co. Faces Difficulties, but Its Gross Margin Is at an Unprecedented 60%

Kontoor Brands: Closing The Gap

Levi Strauss & Co ( ($LEVI) ) has provided an announcement. Levi Strauss & Co. announces the appointment of Dan Geballe to its Board of Directors, ...

Levi Strauss & Co Appoints Dan Geballe to Board

In a report released today, Dana Telsey from Telsey Advisory maintained a Buy rating on Levi Strauss & Co (LEVI – Research Report), with a price ta...

Levi Strauss & Co (LEVI) Receives a Buy from Telsey Advisory

Levi seeing interest for Dockers brand; sees sale in 6 to 9 months - Bloomberg

Amazon preps for a busy Black Friday to Cyber Monday holiday period

We saw the markets take off like a shot in the wake of Trump's decisive election victory last week.

How The Trump Bump Could End In A Slump

The consumer goods industry is at the start of a significant transformation driven by advances in technology and changing consumer preferences. Therefore, it could be wise to buy fundamentally strong stocks, such as Levi Strauss (LEVI), Chewy (CHWY), and Ennis (EBF). Keep reading… The consumer goods industry encompasses a diverse array of products that cater to consumers' everyday needs and preferences worldwide. From personal care items to electronic devices, the consumer goods sector plays a crucial role in driving economic growth, shaping consumer lifestyles, and influencing market trends.
Given the industry's tailwinds, investors could consider buying fundamentally sound consumer stocks, Levi Strauss &amp; Co. (<a href="https://stocknews.com/stock/LEVI/">LEVI</a>), Chewy, Inc. (<a href="https://stocknews.com/stock/CHWY/">CHWY</a>), and Ennis, Inc. (<a href="https://stocknews.com/stock/EBF/">EBF</a>).
Technology integration, particularly through artificial intelligence, <a href="https://www.verifiedmarketresearch.com/rcategory/consumer-goods/">is enabling more personalized customer experiences</a>, efficient product development, and improved supply chain management. Digital tools are also helping companies reduce costs and accelerate innovation, giving leaders a competitive edge.
Additionally, according to Statista, the consumer goods market is projected to reach $2.80 trillion in 2024, with an expected <a href="https://www.statista.com/outlook/io/manufacturing/consumer-goods/worldwide">CAGR of 1.2%</a> by 2029. This sector with strong brand loyalty could offer a stable investment choice, as companies enjoy consistent demand for their products, even during economic downturns. Loyal customers are less sensitive to price changes, helping maintain reliable cash flow.
Considering these favorable trends, let's take a closer look at the fundamentals of the three <a href="https://stocknews.com/category/consumer-goods/">Consumer Goods</a> picks, starting with number #3.
Stock #3: Levi Strauss &amp; Co. (<a href="https://stocknews.com/stock/LEVI/">LEVI</a>)
LEVI designs, markets, and sells apparel and related accessories for men, women, and children worldwide. The company offers jeans, casual and dress pants, activewear, tops, shorts, skirts, dresses, jumpsuits, shirts, sweaters, jackets, footwear, and related accessories under the Levi's, Dockers, Signature by Levi Strauss &amp; Co., Denizen, and Beyond Yoga brands.
LEVI's trailing-12-month levered FCF margin and EBIT margin of 9.98% and 9.36% are 111.8% and 16.9% higher than the industry averages of 4.71% and 8.01%, respectively.
For the fiscal third quarter that ended August 25, 2024, LEVI's net revenues increased 47.6% year-over-year to $1.52 billion. Its operating income stood at $30.30 million. Also, the company's <a href="https://www.investopedia.com/terms/a/adjusted-ebitda.asp">adjusted EBITDA</a> rose 25.6% from the year-ago value to $225.30 million.
Moreover, LEVI's adjusted net income and adjusted EPS came in at $131.90 million and $0.33, increased 17.8% and 17.9% year-over-year, respectively.
Analysts expect LEVI's revenue for the fiscal fourth quarter ending November 2024 to increase 5.2% year-over-year to $1.73 billion. In addition, the company's EPS for the same quarter is expected to increase 9.2% year-over-year to $0.48.
Shares of LEVI have surged 10.3% over the past year and 3.5% year-to-date to close the last trading session at $17.11.
LEVI's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its robust outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
LEVI has a B grade for Growth, Sentiment, and Quality. The stock is ranked #6 out of 55 stocks in the <a href="https://stocknews.com/category/consumer-goods/">Consumer Goods</a> industry.
To see the other ratings of LEVI for Value, Momentum, and Stability, <a href="https://stocknews.com/stock/LEVI/">click here</a>.
Stock #2: Chewy, Inc. (<a href="https://stocknews.com/stock/CHWY/">CHWY</a>)
CHWY engages in the pure-play e-commerce business in the United States. It provides pet food and treats, pet supplies and pet medications, and other pet health products, as well as pet services for dogs, cats, fish, birds, small pets, horses, and reptiles through its retail websites and mobile applications. 
In terms of the trailing-12-month ROCE, CHWY's 85.16% is 698.2% higher than the 10.67% industry average. Its 11.69% trailing-12-month ROTA is 198.7% higher than the 3.91% industry average.
CHWY's net sales for the third quarter ended July 28, 2024, increased 2.5% year-over-year to $2.86 billion. The company's gross profit rose 7% over the prior-year quarter to $843.84 million. In addition, its net income and EPS rose considerably from the year-ago values to $299.12 million and $0.68, respectively.
For the quarter ended October 31, 2024, CHWY's EPS and revenue are expected to increase 51.5% and 4.3% year-over-year to $0.23 and 2.86 billion, respectively. It surpassed Street EPS estimates in each of the trailing four quarters. CHWY's stock has gained 70.6% over the past year to close the trading session at $34.62.
CHWY's strong fundamentals are reflected in its POWR Ratings. It has an overall rating of B, translating to a Buy in our proprietary rating system.
It has an A grade for Growth and Sentiment and a B for Quality. It is ranked #5 in the same industry. To access additional grades of CHWY for Stability, Momentum, and Value ratings, <a href="https://stocknews.com/stock/CHWY/">click here</a>.
Stock #1: Ennis, Inc. (<a href="https://stocknews.com/stock/EBF/">EBF</a>)
EBF manufactures and sells business forms and other business products in the United States. The company offers snap sets, continuous forms, laser cut sheets, tags, labels, envelopes, integrated products, jumbo rolls, and pressure-sensitive products under the Ennis, Royal Business Forms, Block Graphics, 360º Custom Labels, ColorWorx, Enfusion, Uncompromised Check Solutions, VersaSeal, and Ad Concepts.
EBF's trailing-12-month EBIT margin and net income margin of 12.81% and 10.15% are 23.3% and 55.3% higher than the industry averages of 10.38% and 6.54%, respectively.
EBF's net earnings for the fiscal second quarter that ended August 31, 2024, were reported at $10.31 million. The company's gross profit stood at $29.78 million. Also, its net earnings were reported at $10.31 million and 0.40 per share. Furthermore, the company's total assets stood at $406.81 million as of August 31, 2024, compared to $399.19 million as of February 29, 2024.
The company's revenue is expected to be $98.30 million for the third quarter ending November 2024. The company's EPS is expected to be $0.39 for the same quarter. 
Over the past month, EBF's stock has gained 3.1% to close the last trading session at $21.15.
EBF's POWR Ratings reflect its solid prospects. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. 
EBF has an A grade for Quality and a B for Value. Within the same industry, it is ranked #2.
To see EBF's additional ratings for Stability, Growth, Momentum, and Sentiment, <a href="https://stocknews.com/stock/EBF/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
LEVI shares were trading at $16.87 per share on Tuesday afternoon, down $0.24 (-1.40%). Year-to-date, LEVI has gained 4.83%, versus a 27.48% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Nidhi Agarwal</h2> <img src='https:/wp-content/uploads/2023/03/Nidhi-Agarwal_Headshot-3.jpg' style="float:left; padding:5px;width:125px;">Nidhi is passionate about the capital market and wealth management, which led her to pursue a career as an investment analyst. She holds a bachelor's degree in finance and marketing and is pursuing the CFA program.

Her fundamental approach to analyzing stocks helps investors identify the best investment opportunities.<a href="https://stocknews.com/authors/?author=nidhi-agarwal">More...</a>The post <a href=https://stocknews.com/news/levi-chwy-ebf-3-consumer-goods-stocks-with-strong-brand-loyalty/>3 Consumer Goods Stocks With Strong Brand Loyalty</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Comments

Levi Strauss

매도 수량

Levi Strauss (NYSE:LEVI) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌